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Material and methods
All diagnostic surgical lung biopsies performed for diffuse
nodular or interstitial pulmonary disease at 3 university-affil-
iated hospitals between July 1, 1992, and December 31, 1998,
were retrospectively reviewed. Patients with solitary nodules
or other focal pulmonary processes were excluded.
Elective operations were defined as scheduled admissions
to the hospital exclusively for the operative procedures.
Urgent operations were defined as biopsies performed during
hospitalization for respiratory failure in patients not requiring
100% non-rebreather face mask oxygen supplementation or
mechanical ventilation. Emergency biopsies were defined as
biopsies performed during hospitalization for respiratory fail-
ure in patients receiving 100% non-rebreather face mask oxy-
gen supplementation or mechanical ventilation.
Significant beneficial therapeutic changes were defined as
new treatments initiated as a result of the lung biopsy.
Withdrawal of medications, withdrawal of other therapies, or
withdrawal of life support were not considered significant
L ung biopsy is eventually performed in 1 of 3 patientswith interstitial lung disease of unknown cause.
However, it is associated with a substantial mortality
rate. We reviewed our experience with this procedure to
determine whether the mortality rate is outweighed by
vital therapeutic interventions and a survival benefit.
Objective: Lung biopsy is associated with substantial mortality rates. We
reviewed our experience with this operation, primarily in patients with
immunocompetence, to determine whether the results justify the contin-
ued performance of this procedure. Methods: We conducted a retrospec-
tive review of all diagnostic lung biopsies performed at 3 university-affil-
iated hospitals between July 1, 1992, and December 31, 1998. Results:
There were 75 patients: 25 patients were treated electively, 17 were
treated on an urgent basis, 27 patients on an emergency basis, and the
urgency was unclear in 6 patients. Significant beneficial therapeutic
changes were made in 15 of 25 elective procedures (60%), in 16 of 17
urgent procedures (94%), and in 11 of 27 emergency procedures (41%;
P = .001). Significant beneficial therapeutic changes consisted of
immunosuppression in 13 of 15 (87%) patients treated on an elective
basis, in 9 of 16 (56%) treated on an urgent basis, and in 9 of 11 (82%)
treated on an emergency basis in whom therapy was altered (P = .14).
Operative death was 0 of 25 for elective operations (0%), 3 of 17 for
urgent operations (18%), and 14 of 26 for emergency operations (54%).
Multivariable analysis of operative death showed urgency to be the only
significant predictor of death (P = .002). Conclusions: In patients with
immunocompetence, elective and urgent lung biopsies have acceptable
operative mortality rates and frequently result in important beneficial
therapeutic changes. Consequently biopsies are appropriate in these
patients. Emergency biopsies are associated with high operative mortal-
ity rates and rarely result in a therapeutic change other than immuno-
suppression. These patients should not undergo lung biopsy if they are
in stable condition and should be treated empirically with immunosup-
pression without operation if their condition is deteriorating. (J Thorac
Cardiovasc Surg 1999;118:1097-100)
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beneficial therapeutic changes. Operative death was defined
as death during the same hospitalization or within 30 days of
the operation.
Results were analyzed by age, sex, urgency, technique, biop-
sy site, diagnostic yield, pathologic results, culture results,
whether a significant beneficial therapeutic change was made,
type of therapy change, and operative mortality rate.
Comparisons between groups were performed with the
Fisher exact test for univariable analysis. Multivariable step-
wise logistic regression was performed for operative death of
all candidate variables. These variables included age, sex,
urgency, surgical technique, significant beneficial therapeutic
change, and type of therapy change. Histologic diagnosis was
established by review of pathologic reports.
Results
Twenty-six patients were female, and 49 patients
were male. The mean age was 56 years (range 7-85
years). There were 75 biopsies performed. The num-
bers of biopsies performed per year were 3 (0 elective,
1 urgent, 1 emergency, 1 urgency unknown) in 1992, 13
(3 elective, 2 urgent, 5 emergency, 3 urgency unknown)
in 1993, 11 (5 elective, 2 urgent, 2 emergency, 2
urgency unknown) in 1994, 10 (5 elective, 1 urgent, 4
emergency) in 1995, 19 (6 elective, 4 urgent, 9 emer-
gency) in 1996, 11 (4 elective, 4 urgent, 3 emergency)
in 1997, and 8 (2 elective, 3 urgent, 3 emergency) in
1998 (P = .9).
Open procedures were performed in 0 of 25 of elec-
tive operations (0%), in 4 of 17 urgent operations
(24%), and in 24 of 27 emergency operations (89%; P
< .001). Video thoracoscopic procedures were per-
formed whenever possible. Open procedures were cho-
sen for critically ill patients to minimize operative time,
avoid reintubation with a double lumen tube, and
abstain from single lung ventilation.
The site of the biopsy was the lingula in 42 cases, left
upper lobe otherwise not specified in 1 case, left lower
lobe in 27 cases, right upper lobe in 9 cases, right mid-
dle lobe in 9 cases, right lower lobe in 16 cases, and
unspecified sites in 6 patients. There was no significant
difference in the location of the biopsies between the
urgency groups (P = .24). Thirty-four patients under-
went biopsy of a single location; 31 patients had biop-
sies obtained from 2 lobes; and 4 patients had biopsies
obtained from 3 lobes.
A diagnosis was achieved in 100% of patients. Usual
interstitial pneumonia, bronchiolitis, diffuse alveolar
damage, honeycomb lung, and pneumonia were the
most common diagnoses (Table I). Diffuse alveolar
damage was significantly more common in patients
requiring emergency treatment; bronchiolitis was sig-
nificantly more common in the group treated elective-
ly, and granulomatous disease (infectious and nonin-
fectious) was significantly more common in those
receiving urgent treatment. Otherwise, there were no
significant differences in histologic diagnosis between
urgency groups.
Aerobic and anaerobic cultures results were available
for 64 patients. Only 2 of 64 cultures (3%) were posi-
tive for organisms: Propionibacterium acnes in 1 case
and coagulase-negative Staphylococcus in the other
case. Both were thought to be contaminants, and the
results were disregarded. Tuberculosis culture results
were available for 58 patients. None of the results were
positive for tuberculosis, and none of the results were
useful clinically. Fungal culture results were available
for 57 patients. Only 4 of 57 cultures (7%) were posi-
tive for fungal organisms: Candida was identified in 2
patients, Penicillium and Geotrichum were identified in
1 patient, and Histoplasma was identified in 1 patient.
All but the Histoplasma were thought to be contami-
nants and not useful clinically. Although the Histo-
plasma represented true infection, it had already been
diagnosed on the histologic specimen. Viral cultures
were not routinely sent. The diagnosis of viral infec-
tions were most commonly made by findings on histo-
logic sections.
Significant beneficial therapeutic changes were made
in 15 of 25 elective biopsies (60%), in 16 of 17 urgent
biopsies (94%), in 11 of 27 emergency biopsies (41%),
and in 42 of 69 biopsies (61%) overall (P = .001; the
changes made for 6 patients are unknown). Significant
beneficial therapeutic changes in patients undergoing
elective biopsy consisted of treatment with steroids,
azathioprine, and/or cyclophosphamide in 13 of 15
patients (87%) and chemotherapy in 2 of 15 patients
(13%). Significant beneficial therapeutic changes in
patients undergoing urgent biopsy consisted of treat-
ment with steroids, azathioprine, or cyclophosphamide
(or a combination) in 9 of 16 patients (82%), antiviral
therapy in 1 of 16 patients (6%), antifungal therapy in
2 of 16 patients (13%), antibacterial antibiotics with
steroids in 1 of 16 patients (6%), chemotherapy in 1 of
16 patients (6%), and heparin with or without steroids
in 2 of 16 patients (13%). Significant beneficial thera-
peutic changes in patients undergoing emergency biop-
sy consisted of treatment with steroids, azathioprine, or
cyclophosphamide (or a combination) in 9 of 11
patients (82%), antiviral therapy in 1 of 11 patients
(9%), and heparin with steroids in 1 of 11 patients
(9%). There were no significant differences in the
usage of immunosuppression among patients having
therapy changes within the 3 urgency groups (P = .14).
No patient died of surgical complications; however,
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many of the deaths occurred when life support was
withdrawn after the diagnosis of irreversible end-stage
pulmonary disease was established. Overall operative
death occurred in 20 of 73 patients (27%; 2 patients
unknown). There were no operative deaths in the elec-
tive group, 3 (18%) operative deaths among 17 patients
receiving urgent treatment, and 14 (54%) operative
deaths among 26 patients requiring emergency treat-
ment. With the use of univariable analysis, operative
death was strongly associated with urgency (P < .001)
and the use of open surgical technique (P < .001; Table
II). With multivariable logistic regression analysis,
only urgency remained as significant predictor of oper-
ative death (P = .002).
Discussion
Previously reported results of lung biopsy depend
significantly on the immunologic status of the patient.
Because most of our patients were immunocompetent,
we analyzed our results on the basis of the urgency of
the procedure rather than the immunologic status. Our
population was fairly evenly divided with 33% of
patients undergoing elective biopsies, 23% undergoing
urgent biopsies, and 36% undergoing emergency pro-
cedures. Because of lower diagnostic yields, it was rare
for patients to have undergone transbronchial lung
biopsy before referral for surgical lung biopsy.
Consequently, we did not review the results of trans-
bronchial lung biopsies.
The number of biopsies, size of biopsies, blood loss,
operative time, and diagnostic yield are equivalent for
open and thoracoscopic techniques. However, duration
of chest tube drainage, total days of hospitalization,
and total cost are decreased by use of the thoracoscopic
technique.1,2 Therefore our preference is to use thora-
coscopic procedures for elective and urgent surgical
lung biopsies. We use open biopsies in patients referred
for emergency biopsies. These patients are vulnerable
to the risks of increased operative time, reintubation
with a double-lumen endotracheal tube, and single lung
ventilation. Consequently, the urgency and technique
of the procedures are closely related. This approach has
been advocated by others.3,4
Laterality and site of biopsy were chosen to facilitate
the surgical procedure. All patients in this series had dif-
fuse disease; and, with few exceptions, identification of
target regions was unnecessary. The lingula and right
middle lobe were frequently sampled. These regions have
been shown to be satisfactory locations for lung biopsy.5,6
Our diagnostic yield was 100%. This compares
favorably to reported rates in patients who are immuno-
competent of 71% to 100%.1,7,8 Usual interstitial pneu-
monia, bronchiolitis, diffuse alveolar damage, honey-
comb lung, and pneumonia were our most common
diagnoses. Others have reported usual interstitial pneu-
monia in 27% of patients who are immunocompetent,
bronchiolitis in 18% to 26% of patients who are
immunocompetent, malignancy in 5% to 13% of
patients who are immunocompetent, and infection in
0% to 4% of patients who are immunocompetent.1,7,8
Previous reports site 0% to 10% yields for bacterial,
fungal, and viral cultures in the elective setting.1,7 In
patients who are immunocompetent, infection has been
found in only 4% of patients undergoing open lung
biopsies.8 Although we routinely obtained cultures, we
found no clinically significant positive cultures for aer-
obic bacteria, anaerobic bacteria, or mycobacteria. A
single fungal culture was clinically useful and resulted
in treatment. The few viral, protozoal, and fungal infec-
tions in our series were generally diagnosed pathologi-
cally. Thus it appeared that routine cultures were not
necessary in our series of predominantly patients who
were immunocompetent.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 6
Temes et al   1099
Table I. Histologic diagnosis in 66 patients*
Diagnosis Elective Urgent Emergency Total P value
DAD 0 0 11 11 <.001
Bronchiolitis 8 3 1 12 .03
Granulomatous 1 4 0 5 .01
UIP 15 7 10 32 .4
DIP 1 0 0 1 1.0
Honeycomb 4 4 2 10 .4
Emboli/thrombi 0 2 3 5 .17
Vasculitis 0 0 3 3 .11
Pneumonia 2 2 6 10 .3
Malignancy 2 2 0 4 .18
Hemorrhage 0 1 2 3 .4
DAD, Diffuse alveolar damage; UIP, usual interstitial pneumonia; DIP, diffuse
interstitial pneumonia.
*Six patients in whom the urgency was unknown are not included; more than
1 diagnosis was made in some patients.
Table II. Analysis of operative death by possible risk
factors
Univariable Multivariable 
models models 
Risk factor (P value) (P value)
Urgency <.001 .002
Open vs scope <.001 .17
Male vs female .6 .7
Aged > 70 y .5 .8
Therapy change vs none .6 .3
Immunosuppression vs none .2 .9
Significant beneficial therapeutic changes were made
in 61% of our patients as a result of lung biopsy.
Previous authors have reported changes in therapy in
46% to 54% of all patients undergoing open lung biop-
sy and in 18% to 41% of patients who are immuno-
competent.7,8 These data are difficult to interpret
because definitions vary between authors. Significant
beneficial therapeutic changes in our patients consisted
of immunosuppression in 87% of elective cases, 56%
of urgent cases, and 82% of emergency cases.
Significant beneficial therapeutic changes other than
immunosuppression occurred in 11 of 69 of the entire
group (16%) in whom therapy after biopsy is known.
Previous reports have documented overall operative
mortality rates of 0% to 60%.7-9 Our overall operative
mortality rate was 27%. Operative mortality rates in
patients who are immunocompetent has been reported
as 0% to 7% with elective treatment, 10% with urgent
treatment, and 33% to 66% with emergency treatment;
again definitions vary.4,9-11 Our mortality rate depend-
ed significantly on urgency (elective treatment, no
deaths; urgent treatment, 18% mortality; emergency
treatment, 54% mortality). In many instances, death
resulted from the withdrawal of care in patients who
were expected to have minuscule chances for recovery.
With the use of univariable analysis, urgency and use of
open surgical technique were significantly associated
with operative death. With multivariable logistic
regression analysis, only urgency remained as signifi-
cant predictor. We and others have been unable to
demonstrate decreased operative death between
patients who received new therapies after biopsy and
those who did not.4,7,10,12
Should lung biopsy be performed? Patients undergo-
ing elective biopsy have no operative deaths, and 60%
obtain significant beneficial therapeutic changes.
Patients undergoing urgent biopsy have an 18% opera-
tive mortality rate, but 94% receive significant beneficial
therapeutic changes. There is no significant difference in
operative survival between those with significant benefi-
cial therapeutic changes and those without significant
beneficial therapeutic changes. To determine whether
lung biopsy is advantageous, a comparison between
those who undergo biopsy and those who are treated
empirically should be performed. Until then, biopsies are
appropriate in elective and urgent situations.
Conversely, patients undergoing emergency biopsy
have an operative mortality rate of 54%, and only 7%
receive significant beneficial therapeutic changes other
than immunosuppression. There is no significant dif-
ference in operative survival between those patients
receiving significant beneficial therapeutic changes and
those patients who do not. A comparison between those
patients who undergo biopsy and those patients who
are treated empirically should be performed. Until
then, these patients should not receive diagnostic surgi-
cal procedures if they are in stable condition. They
should be treated empirically with immunosuppression
without operation if their condition is deteriorating.
This approach avoids the risk, cost, and potential lia-
bilities of a surgical procedure that has no apparent or
proven benefit to the patient. 
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